Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 6/20 | 0.48 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7628259 | 0.98 | HTR7 (0.48) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL10930120 | 0.97 | HTR7 (0.47) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL219876 | 0.90 | HRH1 (0.59) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL10932211 | 0.89 | HRH3 (0.48) | HTR7HRH3DRD3TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL219199 | 0.89 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL5686168 | 0.89 | HRH1 (0.60) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL2058761 | 0.88 | HRH1 (0.57) | HTR7HRH3BCL2BAK1HRH1 | |
| Potassium Ion SCHEMBL2058535 | 0.88 | HTR7 (0.49) | HTR7HRH3BCL2BAK1HRH1 | |
| Hydrochloric Acid SCHEMBL10930701 | 0.87 | HRH1 (0.58) | HTR7HRH3BCL2BAK1HRH1 | |
| SCHEMBL11125568 | 0.87 | HTR7 (0.54) | HTR7HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| EP-0955295-B1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB SA (BE) | 2004-05-19 | — | — | EP | claimed |
| EP-1413307-A1 | Therapeutically active levorotatory and dextrorotatory 1-(4-chlorophenyl)phenylmethyl piperazines | UCB S.A. (BE) | 2004-04-28 | — | — | EP | claimed |
| EP-0955295-A1 | Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines | UCB, S.A. (BE) | 1999-11-10 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| EP-2307392-A2 | PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN | Cipla Limited (IN) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009147389-A2 | PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN | CIPLA LIMITED (IN) | 2009-12-10 | — | — | WO | disclosed |
| US-7619085-B2 | Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine | UCB PHARMA, S.A. (BE) | 2009-11-17 | — | — | US | disclosed |
| EP-1858866-B1 | PYROGLUTAMATE SALTS AND THEIR USE IN THE OPTICAL RESOLUTION OF INTERMEDIATES FOR THE SYNTHESIS OF DEXTROCETIRIZINE AND LEVOCETIRIZINE | UCB FARCHIM SA (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080269489-A1 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine | UCB PHARMA, S.A. (BE) | 2008-10-30 | — | — | US | disclosed |
| EP-0927173-A1 | SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB, S.A. (BE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1997037982-A1 | NOVEL SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB S.A. (BE) | 1997-10-16 | — | — | WO | disclosed |
| US-5478941-A | Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity | U C B, S.A. (BE) | 1995-12-26 | — | — | US | disclosed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
| EP-0058146-B1 | 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | U C B, S.A. (BE) | 1984-06-27 | — | — | EP | disclosed |
| EP-0058146-A1 | 2-(4-(Diphenylmethyl)-1-piperazinyl)-acetic acids and their amides, process for their preparation and pharmaceutical compositions | U C B, S.A. (BE) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CYP3A5, CYP4A11, IL5 | HTR7 831/4885HRH3 437/4885BCL2 4682/4885 |
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | HTR7 169/4885HRH3 1206/4885BCL2 3769/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | HTR7 163/4885HRH3 1275/4885BCL2 3811/4885 |
| US-20080269489-A1 | Pyroglutamate Salts and Their Use in the Optical Resolution of Intermediates for the Synthesis of Dextrocetirizine and Levocetirizine | QPCT, QRFPR, GLUL | HTR7 3100/4885HRH3 1550/4885BCL2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.